<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25484" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Myopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nagy</surname>
            <given-names>Hassan</given-names>
          </name>
          <aff>Ain Shams University Hospitals</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Veerapaneni</surname>
            <given-names>Karthika Durga</given-names>
          </name>
          <aff>University of Arkansas Medical Sciences</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hassan Nagy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karthika Durga Veerapaneni declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25484.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Myopathies are a heterogeneous group of disorders primarily affecting the skeletal muscle structure, metabolism or channel function. They usually present with muscle weakness interfering in daily life activities. Muscle pain is also a common finding and some myopathies are associated with rhabdomyolysis. This activity reviews the classification, presentation patterns and highlights the role of interprofessional team in diagnosis and management of a suspected muscle disorder.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the presentation patterns of common myopathies.</p></list-item><list-item><p>Describe the diagnostic approach of a suspected myopathy.</p></list-item><list-item><p>Outline the management of a suspected myopathy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25484&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25484">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25484.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Myopathy is derived from the Greek words &#x0201c;myo&#x0201d; for muscle, and &#x0201c;pathy&#x0201d; for suffering which means muscle disease. The most common signs and symptoms of myopathies include weakness, stiffness, cramps, and spasms. Myopathies are a heterogeneous group of disorders primarily affecting the skeletal muscle structure, metabolism, or channel function. They usually present with muscle weakness interfering in daily life activities. Muscle pain is also a common finding and some myopathies are associated with rhabdomyolysis.</p>
      </sec>
      <sec id="article-25484.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of the myopathies is usually caused by a disruption in the muscle tissue integrity, and the metabolic stability which may be triggered by inherited genetic diseases, or metabolic errors, certain drugs and toxins, bacterial or viral infections, inflammation, besides minerals, electrolytes, and hormonal irregularities:</p>
        <p>&#x000a0;<bold>Inherited Myopathies</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Mitochondrial Myopathies<xref ref-type="bibr" rid="article-25484.r1">[1]</xref>
<list list-type="bullet"><list-item><p>Mitochondrial encephalopathy,&#x000a0;lactic acidosis, and strokelike&#x000a0;syndrome (MELAS)</p></list-item><list-item><p>Kearns-Sayre syndrome</p></list-item><list-item><p>Others (Leber hereditary optic&#x000a0;neuropathy; Myoclonic epilepsy with&#x000a0;ragged red fibers; Leigh syndrome and&#x000a0;neuropathy, ataxia, and&#x000a0;retinitis pigmentosa;&#x000a0;mtDNA deletion and&#x000a0;depletion syndromes;&#x000a0;Chronic&#x000a0;progressive external&#x000a0;ophthalmoplegia; etc.)<xref ref-type="bibr" rid="article-25484.r1">[1]</xref>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Congenital Myopathies
<list list-type="bullet"><list-item><p>Nemaline myopathies<xref ref-type="bibr" rid="article-25484.r2">[2]</xref></p></list-item><list-item><p>Core myopathies</p></list-item><list-item><p>Centronuclear myopathies</p></list-item><list-item><p>Others<xref ref-type="bibr" rid="article-25484.r3">[3]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Metabolic Myopathies<xref ref-type="bibr" rid="article-25484.r4">[4]</xref>
<list list-type="bullet"><list-item><p>Lipid myopathies (most common are carnitine palmitoyltransferase II deficiency, very-long-chain-acyl-CoA dehydrogenase deficiency, trifunctional&#x000a0;protein deficiency)</p></list-item><list-item><p>Glycogen storage disease myopathy (Acid maltase deficiency - Pompe disease, Debrancher deficiency - Cori disease - and muscle phosphorylase deficiency - McArdle disease - are the most frequently encountered)</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Channelopathies
<list list-type="bullet"><list-item><p>Periodic paralysis (Hypokalemic, hyperkalemic, Andersen-Tawil syndrome)</p></list-item><list-item><p>Nondystrophic myotonias (p.e. paramyotonia congenita, Thomsen disease)</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Muscular Dystrophies<xref ref-type="bibr" rid="article-25484.r5">[5]</xref>
<list list-type="bullet"><list-item><p>Dystrophinopathies (Duchenne muscular dystrophy, Becker muscular dystrophy, Intermediate phenotype)</p></list-item><list-item><p>Myotonic muscular dystrophies (type 1 and type 2)</p></list-item><list-item><p>Facioscapulohumeral muscular dystrophies&#x000a0;(type 1 and type 2)</p></list-item><list-item><p>Emery-Dreifuss&#x000a0;muscular dystrophy</p></list-item><list-item><p>Limb-girdle muscular dystrophies</p></list-item><list-item><p>Oculopharyngeal muscular dystrophy</p></list-item><list-item><p>Congenital muscular dystrophy (most common being LAMA2-related, collagen VI-related and alfa-dystroglycan-related)&#x000a0;&#x000a0;</p></list-item><list-item><p>Distal myopathies&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Acquired Myopathies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Toxic Myopathies
<list list-type="bullet"><list-item><p>Necrotizing myopathies (statins, fibrates, immune checkpoint inhibitors, labetalol, propofol, alcohol, cyclosporine)<xref ref-type="bibr" rid="article-25484.r6">[6]</xref><xref ref-type="bibr" rid="article-25484.r7">[7]</xref></p></list-item><list-item><p>Mitochondrial myopathies (some antiretrovirals)</p></list-item><list-item><p>Amphiphilic myopathies (chloroquine, hydroxychloroquine, amiodarone)</p></list-item><list-item><p>Antimicrotubular myopathies&#x000a0; (vincristine)</p></list-item><list-item><p>Hypokalemic myopathies (diuretics, steroids, laxatives, alcohol, etc.)</p></list-item><list-item><p>Critical care-associated myopathies (corticosteroids, neuromuscular blockers)</p></list-item><list-item><p>Inflammatory myopathy (tumor necrosis alfa inhibitors, immune checkpoint inhibitors, statins, IFN-alfa, D-penicillamine, L-tryptophan, hydroxyurea, imatinib lamotrigine, phenytoin)</p></list-item><list-item><p>Unknown mechanism (finasteride, omeprazole, isotretinoin)<xref ref-type="bibr" rid="article-25484.r7">[7]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Immune-mediated or Idiopathic Inflammatory Myopathies
<list list-type="bullet"><list-item><p>Dermatomyositis</p></list-item><list-item><p>Antisynthetase syndrome</p></list-item><list-item><p>Immune-mediated necrotizing myopathy</p></list-item><list-item><p>Inclusion body myopathy</p></list-item><list-item><p>Overlap myositis (association with other connective tissue diseases as systemic lupus erythematosus, Sjogren syndrome, systemic sclerosis, and rheumatoid arthritis)</p></list-item><list-item><p>Polymyositis<xref ref-type="bibr" rid="article-25484.r8">[8]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Infectious Myopathies&#x000a0;
<list list-type="bullet"><list-item><p>Bacterial infections (Lyme disease, pyomyositis -&#x000a0;Staphylococcus aureus)</p></list-item><list-item><p>Viral infections (Human immunodeficiency virus (HIV),&#x000a0;Coxsackie A and B viruses,&#x000a0;Influenza)</p></list-item><list-item><p>Parasitic infections (trichinosis, toxoplasmosis, cysticercosis)<xref ref-type="bibr" rid="article-25484.r9">[9]</xref><xref ref-type="bibr" rid="article-25484.r10">[10]</xref><xref ref-type="bibr" rid="article-25484.r11">[11]</xref>&#x000a0;</p></list-item><list-item><p>Fungal infection (Candida, Coccidiomycosis)<xref ref-type="bibr" rid="article-25484.r8">[8]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Endocrine Myopathies&#x000a0;<xref ref-type="bibr" rid="article-25484.r12">[12]</xref>
<list list-type="bullet"><list-item><p>Thyroid and parathyroid dysfunction (hyperthyroidism, hypothyroidism, hyperparathyroidism)</p></list-item><list-item><p>Adrenal dysfunction (Addison's disease, Cushing syndrome)</p></list-item><list-item><p>Diabetic muscle infarction</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Electrolyte-mediated Mopathies (hypo- and hyperkalemia, hypercalcemia, hypermagnesemia, hypophosphatemia)</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Myopathies associated with systemic disease (amyloidosis, sarcoidosis, vitamin D deficiency, critical care myopathy, idiopathic eosinophilic myopathy, paraneoplastic)</p>
          </list-item>
        </list>
        <p>NOTE: Rhabdomyolysis is a syndrome defined by skeletal muscle damage&#x000a0;with CK elevation. It can occur with or without underlying muscle disease and should not be considered as a primary myopathy.<xref ref-type="bibr" rid="article-25484.r8">[8]</xref></p>
      </sec>
      <sec id="article-25484.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Inflammatory and endocrine myopathies are a more common type of myopathy in general which usually in middle-aged women&#x0003e; men. It was found that the incidence rate of inflammatory myopathies varied between 1.16 to 19/million/year while the prevalence varied between 2.4 to 33.8 per 100,000 population.<xref ref-type="bibr" rid="article-25484.r13">[13]</xref></p>
        <p>The most common inherited myopathies are the dystrophinopathies, which are more common in male patients and affect every race and ethnicity equally. Amongst them, Duchenne's and Becker's muscular dystrophy are the most prevalent which varied between 19.8 and 25.1 per 100,000 person-years.<xref ref-type="bibr" rid="article-25484.r14">[14]</xref> Mitochondrial myopathies affect 1 in 4300 people. Other forms of inherited myopathies are rare.<xref ref-type="bibr" rid="article-25484.r14">[14]</xref></p>
      </sec>
      <sec id="article-25484.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Myopathies are typically involving motor impairment without no sensory symptoms. It presents as proximal muscle weakness, mainly in the pelvic girdle or the shoulder girdle muscle groups. However, pelvic muscle group is more common and more severe. Comprehensive history alongside physical examination is mandatory to identify and diagnose myopathies. Patients may complain of difficulty raising up from sitting position, climbing stairs or difficulty brushing their hair, or practicing any above head activities.&#x000a0;Some other myopathies will present in different muscle groups like thighs, back muscles, or fingers, and could be possibly associated with other symptoms like myalgia, rashes, fatigue, or cramps. Muscle disease could also present with dark urine as a sign of renal damage in the case of rhabdomyolysis, particularly after vigorous exercises like running marathons.</p>
        <p><bold>Polymyositis and dermatomyositis</bold>: Both of them affect women more than men, present with proximal weakness affects pelvic girdle more than shoulder girdle. Polymyositis is associated with arthralgia while dermatomyositis is associated with other symptoms mainly skin manifestations including a purple rash on the eyelids called heliotrope rash, an erythematous scaly rash appears on the dorsum of the fingers called Gottron's papules, a reddish rash appears on the shoulder and the back known as Shawl sign, besides interstitial lung disease, Gastrointestinal vasculitis, and paraneoplastic syndrome underlying malignancy.<xref ref-type="bibr" rid="article-25484.r15">[15]</xref></p>
        <p><bold>Hypothyroid and hyperthyroid myopathies</bold>: Both of them are associated with the thyroid disease whether it is hypo- or hyperthyroid disease, and both present with proximal muscle weakness and peripheral neuropathy. Hypothyroid myopathy is associated with pseudohypertrophy, myoedema, and delayed deep tendon reflexes. Hyperthyroid myopathy is associated with Grave's ophthalmopathy, goiter, and extraocular muscle weakness as well.<xref ref-type="bibr" rid="article-25484.r12">[12]</xref><xref ref-type="bibr" rid="article-25484.r16">[16]</xref><xref ref-type="bibr" rid="article-25484.r12">[12]</xref></p>
        <p>Other types of acquired myopathies will represent within a group of symptoms associated with that particular disease like for example sarcoidosis myopathy, amyloid myopathy, and critical illness myopathy.&#x000a0;Duchenne muscular dystrophy, myotonic dystrophy 1,2, mitochondrial myopathies, Glycogen storage diseases like (McArdle, Pompe's disease, etc) are inherited myopathies affect children and it is rare, and accompanied with severe systemic complications. These patients' life expectancy is relatively limited depending on the severity of the disease and the complications.<xref ref-type="bibr" rid="article-25484.r17">[17]</xref></p>
      </sec>
      <sec id="article-25484.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The complementary evaluation should be guided by clinical suspicion. Useful tests include:</p>
        <p>
<bold>&#x000a0;1) Laboratory studies</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete blood count</p>
          </list-item>
          <list-item>
            <p>Blood urea nitrogen and serum creatinine</p>
          </list-item>
          <list-item>
            <p>Electrolytes (sodium, magnesium, potassium, calcium, phosphorus)</p>
          </list-item>
          <list-item>
            <p>Aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH), y-glutamyltransferase (GGT)</p>
          </list-item>
          <list-item>
            <p>Creatine kinase (CK), myoglobin, and aldolase: CK the most useful blood test but levels may not correlate with the degree of muscle weakness. Myopathies with&#x000a0;enhanced regeneration or spared myofibers, such as in antisynthetase syndrome, dermatomyositis, and critical care myopathy, may present with normal CK and selectively elevated aldolase.</p>
          </list-item>
          <list-item>
            <p>C-reactive protein and erythrocyte sedimentation rate</p>
          </list-item>
          <list-item>
            <p>Thyroid function tests&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Anti-nuclear antigen (ANA) and myositis associated antibody panel (importantly -Jo1, -PL7, -PL12, -OJ for antisynthetase syndrome; TIF1-gamma, - NXP2, -Mi2, -SAE, - MDA5 for dermatomyositis, - HMG-CoA, -SRP for immune-mediated necrotizing myopathy)</p>
          </list-item>
          <list-item>
            <p>Urinalysis: positive hemoglobin dipstick without erythrocytes on microscopic evaluation is a sign of myoglobinuria</p>
          </list-item>
        </list>
        <p>
<bold>2) Electromyography (EMG) and nerve conduction study (NCS):<xref ref-type="bibr" rid="article-25484.r8">[8]</xref></bold>
</p>
        <p>In this context electrodiagnostic testing has many objectives:</p>
        <list list-type="order">
          <list-item>
            <p>it is useful to exclude alternative diagnoses such as neuromuscular junction or motor neuron disorders.</p>
          </list-item>
          <list-item>
            <p>it can confirm the myopathic nature of the process if there is an identifiable pattern.</p>
          </list-item>
          <list-item>
            <p>it helps characterized and stratify the severity of the disease</p>
          </list-item>
          <list-item>
            <p>it can help to choose the best location to perform a muscle biopsy.&#x000a0;&#x000a0;</p>
          </list-item>
        </list>
        <p>Motor NCS are usually normal unless there is a concomitant neuropathy. Exceptions to this include distal myopathies and critical care myopathy where low compound muscle action potentials (CMAPs) with normal latencies and conduction velocities are seen.&#x000a0;Sensory NCS&#x000a0;are within normal range...Inclusion body myositis is the exception since it can cause sensory abnormalities.</p>
        <p>Needle EMG is the most sensitive examination for myopathy. The presence of myotonic discharges and muscle membrane irritability (increased insertional activity, fibrillation potentials, and positive sharp waves) helps to narrow the differential diagnosis as it is generally present in necrotizing myopathies (inflammatory or toxic), myotonic dystrophies and a few metabolic&#x000a0;and congenital myopathies. Repetitive stimulation and correlation with exercise may be needed in the special case of channelopathies.</p>
        <p>Complex repetitive discharges and decreased insertional activity are signs of a chronic process.&#x000a0;</p>
        <p>In some metabolic, congenital, endocrine myopathies, electrodiagnostic tests may be normal.</p>
        <p>Of note, electrodiagnostic testing is not&#x000a0;always needed&#x000a0;if there is a strong suspicion of a myopathic disorder (p.e. suggestive clinical features with elevated CK or positive family history), especially in the pediatric population.&#x000a0;<xref ref-type="bibr" rid="article-25484.r18">[18]</xref></p>
        <p><bold>3) Electrocardiography</bold>&#x000a0;<bold>(ECG): </bold>Findings suggestive of hypokalemia include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Diffuse nonspecific ST-T wave changes</p>
          </list-item>
          <list-item>
            <p>Increased PR interval</p>
          </list-item>
          <list-item>
            <p>U waves</p>
          </list-item>
          <list-item>
            <p>Wide QRS</p>
          </list-item>
        </list>
        <p><bold>4) Muscle biopsy: </bold>Muscle biopsies are categorized by three major components:<xref ref-type="bibr" rid="article-25484.r8">[8]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Histological/histochemical</p>
          </list-item>
          <list-item>
            <p>Myopathic vs. neuropathic patterns of disease</p>
          </list-item>
          <list-item>
            <p>Presence of unique features that are clues to underlying pathophysiology and diagnosis</p>
          </list-item>
          <list-item>
            <p>Myopathic pattern</p>
          </list-item>
          <list-item>
            <p>Rounding and variation of myofiber size</p>
          </list-item>
          <list-item>
            <p>Internal nuclei, fiber atrophy, degeneration and regenerating myofibers</p>
          </list-item>
          <list-item>
            <p>Fatty replacement</p>
          </list-item>
          <list-item>
            <p>Neuropathic pattern</p>
          </list-item>
          <list-item>
            <p>Evidence of denervation and re-innervation</p>
          </list-item>
          <list-item>
            <p>Small, atrophic, angular fibers and target fibers</p>
          </list-item>
          <list-item>
            <p>Re-innovation results in fiber type grouping</p>
          </list-item>
        </list>
        <p><bold>5) Muscle MRI:</bold> Magnetic resonance imaging of the muscles:<xref ref-type="bibr" rid="article-25484.r8">[8]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Increased signal intensity within muscle tissue</p>
          </list-item>
          <list-item>
            <p>May see muscle necrosis, degeneration, and/or inflammation</p>
          </list-item>
          <list-item>
            <p>May see fatty replacement, an indicator of chronic muscle damage</p>
          </list-item>
          <list-item>
            <p>Findings may help guide site selection for muscle biopsy</p>
          </list-item>
          <list-item>
            <p>MRI offers a less invasive assessment tool in pediatric populations</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25484.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment for myopathy is generally supportive due to the nature of the etiology of the muscle disease including exercises, physical and occupational therapies, nutrition, and dietetics, and may be genetic analysis and counseling.<xref ref-type="bibr" rid="article-25484.r19">[19]</xref><xref ref-type="bibr" rid="article-25484.r20">[20]</xref></p>
        <p>Inherited muscular dystrophies: Prednisone 0.75 mg/kg/day has presented improvement in muscle strength, increased muscle bulking, and slowed the disease progression. It is also important to anticipate complications and treat them accordingly. In mitochondrial myopathies creatine monohydrate 5-10 g/day may benefit improving the symptoms, Coenzyme Q10 replacement still needs more consistent research results to prove significance.<xref ref-type="bibr" rid="article-25484.r21">[21]</xref><xref ref-type="bibr" rid="article-25484.r18">[18]</xref><xref ref-type="bibr" rid="article-25484.r21">[21]</xref></p>
        <p>Acquired myopathies, in general, improve by treating the main causing disease whether it is a systemic disease like thyroid disease, sarcoidosis. Some acquired myopathies will be caused by infection ( Bacterial, Viral, Fungal, Parasitic, or spirochetes) the myopathy symptoms improve by treating the infection. Toxin or drug-related myopathy is also managed by the removal of the causative agent and avoiding it in the future. HIV-related myopathy is also responding well to antiretroviral therapy HAART, and maybe steroids as well.<xref ref-type="bibr" rid="article-25484.r22">[22]</xref><xref ref-type="bibr" rid="article-25484.r18">[18]</xref></p>
        <p>Inflammatory myopathy and autoimmune related myopathies are treated mainly by immunomodulatory, immunosuppressants, and steroid drugs. It is proved that steroids are better in comparison to immunomodulatory drugs due to side effects. Medications used are methotrexate, azathioprine, cyclosporin, and cyclophosphamide besides oral&#x000a0;dexamethasone and daily oral prednisolone. Unfortunately, some cases including IBMs are refractory to immunosuppressants medication and steroids, and they continue to progress to more generalized weakness.&#x000a0;High quality Randomised clinical trials are needed to determine the effectiveness and toxicity of the immuno-mediated drugs in the treatment of these inflammatory myopathies.<xref ref-type="bibr" rid="article-25484.r23">[23]</xref></p>
        <p>Rhabdomyolysis: The ultimate goal for treatment in rhabdomyolysis is preventing the acute kidney injury by the myoglobin resulting from the muscle damage. Aggressive hydration by IV fluids, and closely monitoring the kidney functions, and the electrolyte balance.<xref ref-type="bibr" rid="article-25484.r18">[18]</xref></p>
      </sec>
      <sec id="article-25484.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis of myopathy is extensive, as it varies depends on the associated symptoms:</p>
        <p><bold>Guillain-Barre syndrome:</bold> The typical patient with GBS, which in most cases will&#x000a0;manifest as&#x000a0;acute inflammatory demyelinating polyradiculoneuropathy (AIDP), presents 2-4 weeks following a relatively benign respiratory or gastrointestinal illness with complaints of finger dysesthesias and proximal muscle weakness of the lower extremities. The weakness may progress over hours to days to involve the arms, truncal muscles, cranial nerves, and muscles of respiration.</p>
        <p><bold>Tick-borne diseases:</bold> The reference standard for the diagnosis of tickborne rickettsial diseases is the indirect immunofluorescence antibody (IFA) assay using paired serum samples obtained soon after illness onset and 2-4 weeks later.</p>
        <p><bold>Lambert-Eaton myasthenic syndrome (LEMS):</bold>&#x000a0; proximal muscle weakness, depressed tendon reflexes, post-tetanic potentiation, and autonomic changes due to impairment in acetylcholine release.</p>
        <p><bold>Myasthenia gravis:</bold>&#x000a0;an autoimmune disorder of peripheral nerves in which antibodies form against acetylcholine (ACh) nicotinic postsynaptic receptors at the myoneural junction. A reduction in the number of ACh receptors results in a characteristic pattern of progressively reduced muscle strength with repeated use of the muscle and recovery of muscle strength following a period of rest. The bulbar muscles are affected most commonly and most severely, but most patients also develop some degree of fluctuating generalized weakness.</p>
        <p>Other differentials include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Malignant hyperthermia</p>
          </list-item>
          <list-item>
            <p>Myotonia</p>
          </list-item>
          <list-item>
            <p>Myositis ossificans</p>
          </list-item>
          <list-item>
            <p>Myositis associated with the vasculitides</p>
          </list-item>
          <list-item>
            <p>Paraneoplastic syndromes&#x000a0;(eg. carcinomatous neuropathy, cachexia, myonecrosis)</p>
          </list-item>
          <list-item>
            <p>Direct muscle damage (trauma, excessive exercise)</p>
          </list-item>
          <list-item>
            <p>Nutritional&#x000a0;deficiencies&#x000a0;(vitamin E deficiency, malabsorption syndromes)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25484.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The treatment goals for most myopathies are to slow or stop the progression of the disease concerning congenital, metabolic, and inflammatory myopathies. Some of the inherited myopathies' complications could be fatal. The health-related quality of life within this category of myopathies such as inflammatory and congenital myopathies is impaired. However. the prognosis of acquired myopathies is dependant on the etiology whether it is the severity of the systemic disease or the nature of the infection, and the damage occurred due to a drug or a toxin. The acquired myopathies are well controlled by&#x000a0;treating the main disease.<xref ref-type="bibr" rid="article-25484.r24">[24]</xref></p>
      </sec>
      <sec id="article-25484.s10" sec-type="Complications">
        <title>Complications</title>
        <p>The complications of the various types of myopathies are largely attributed to the progression of the disease. Congenital, metabolic and hereditary myopathies could have fatal complications like cardiomyopathies, recurrent infections, and sepsis, neuropathies, respiratory failure, or renal failures. On the other hand, the complications of acquired myopathies are relatively limited to the etiology. For example, if it is infectious related then it is dependant on the type of the infection or if it is related to drug or toxin, then it is dependant on the dose and the period, and so on. Here is a list of possible complications:</p>
        <list list-type="bullet">
          <list-item>
            <p>Death</p>
          </list-item>
          <list-item>
            <p>Rhabdomyolysis</p>
          </list-item>
          <list-item>
            <p>Heart arrhythmias</p>
          </list-item>
          <list-item>
            <p>Paraneoplastic syndromes</p>
          </list-item>
          <list-item>
            <p>Heart failure</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Renal failure</p>
          </list-item>
          <list-item>
            <p>Neuropathies: Seizures and cerebral dysplasias</p>
          </list-item>
          <list-item>
            <p>Impaired movement</p>
          </list-item>
          <list-item>
            <p>Bedsores</p>
          </list-item>
          <list-item>
            <p>Infections and sepsis</p>
          </list-item>
          <list-item>
            <p>Irreversible muscle wasting</p>
          </list-item>
          <list-item>
            <p>Recurrent dysphagia</p>
          </list-item>
          <list-item>
            <p>Acute gastric dilation</p>
          </list-item>
          <list-item>
            <p>Respiratory system failure</p>
          </list-item>
          <list-item>
            <p>Endocrinopathies</p>
          </list-item>
          <list-item>
            <p>Cataracts</p>
          </list-item>
          <list-item>
            <p>Sensorineural hearing loss<xref ref-type="bibr" rid="article-25484.r25">[25]</xref><xref ref-type="bibr" rid="article-25484.r26">[26]</xref><xref ref-type="bibr" rid="article-25484.r27">[27]</xref> &#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25484.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Some of the myopathic diseases are chronic and require lifestyle modification. It is highly encouraged to maintain a balanced diet that contacts a variety of fruits and vegetables. In addition to a balanced diet, it is essential to stay active. Physical therapy and moderate exercise plans are recommended. Particularly in patients with metabolic myopathies like lysosomal storage disease and glycogen storage disease, etc.. are encouraged to follow moderate exercise plans besides diet plans that focus on decreasing the causative diet components.</p>
        <p>Inflammatory muscle diseases are chronic diseases. Patients tend to benefit from regular exercise plans alongside medical therapy. Patients are advised to continue to monitor the progression of the disease and the severity of the symptoms and maintain continuous medical care. Inherited myopathies are usually associated with other complications. Anticipating complications is vital in the survival rate, and seeking immediate medical care in cases of emergencies like cardiomyopathies, sepsis. etc.</p>
      </sec>
      <sec id="article-25484.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Myopathies management is highly dependant on an interprofessional team of primary care physicians, family physicians, pediatricians, neurologists, rheumatologists, nephrologists, cardiologists, and even orthopedics. There are also other health care providers that have a great share for the care of this cohort of myopathic patients include dietitians, nutritionists, genetic counselors, mental health counselors, physical therapists, occupational therapists, and speech therapists. It is pivotal to maintain interprofessional communication between all treatment team to slow the progression of different myopathies.</p>
        <p>While the primary care physician or the family physician might be the first person who encounters the patient diagnosis with one of the chronic myopathies, it takes all other specialists to participate in the treatment plans alongside with other medical providers mentioned above. The ultimate outcome to slow the progression of the disease and help patients with inherited myopathies to cope with the disease and to delay the onset of the complications. The multi-professional treatment team together improves the health-related quality of life for myopathic patients.</p>
      </sec>
      <sec id="article-25484.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25484&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25484">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/joint-muscle-and-bone/myopathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25484">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25484/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25484">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25484.s14">
        <fig id="article-25484.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Coagulative Necrosis in Myocytes During Silent Myocardial Ischemia. Small foci of coagulative necrosis can be recognized on hematoxylin and eosin-stained sections: ischaemic myocytes typically show the hypereosinophilia that characterizes early phases of coagulative necrosis. (A) The ischemic myocytes are located on the left side of the panel; (B) the ischemic myocytes are positioned at the bottom left; (C) low magnification view showing a small area of acute myocardial infarction in which granulocyte infiltration is visible among the myocytes showing coagulative necrosis (squared area and (D), inset at higher magnification). The front of the myocardial ischemia is in the top half of the image. Pasotti M, Prati F,&#x000a0;Arbustini E. The pathology of myocardial infarction in the pre- and post-interventional era. <italic toggle="yes">Heart.</italic> 2006;92(11):1552-1556. doi: 10.1136/hrt.2005.086934.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ht86934_f1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25484.s15">
        <title>References</title>
        <ref id="article-25484.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DiMauro</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Mitochondrial myopathies.</article-title>
            <source>Curr Opin Rheumatol</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>636</fpage>
            <page-range>636-41</page-range>
            <pub-id pub-id-type="pmid">17053512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Winter</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ottenheijm</surname>
                <given-names>CAC</given-names>
              </name>
            </person-group>
            <article-title>Sarcomere Dysfunction in Nemaline Myopathy.</article-title>
            <source>J Neuromuscul Dis</source>
            <year>2017</year>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-113</page-range>
            <pub-id pub-id-type="pmid">28436394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nance</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Dowling</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Gibbs</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>B&#x000f6;nnemann</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Congenital myopathies: an update.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>165</fpage>
            <page-range>165-74</page-range>
            <pub-id pub-id-type="pmid">22392505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>El-Gharbawy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koeberl</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Metabolic myopathies: clinical features and diagnostic approach.</article-title>
            <source>Rheum Dis Clin North Am</source>
            <year>2011</year>
            <month>May</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>201</fpage>
            <page-range>201-17, vi</page-range>
            <pub-id pub-id-type="pmid">21444020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wicklund</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>The muscular dystrophies.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>6 Muscle Disease</issue>
            <fpage>1535</fpage>
            <page-range>1535-70</page-range>
            <pub-id pub-id-type="pmid">24305447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomaszewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>St&#x00119;pie&#x00144;</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Tomaszewska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Czuczwar</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Statin-induced myopathies.</article-title>
            <source>Pharmacol Rep</source>
            <year>2011</year>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>859</fpage>
            <page-range>859-66</page-range>
            <pub-id pub-id-type="pmid">22001973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Le Quintrec</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Le Quintrec</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced myopathies.</article-title>
            <source>Baillieres Clin Rheumatol</source>
            <year>1991</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-38</page-range>
            <pub-id pub-id-type="pmid">2070426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gourley</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of inflammatory myopathy: issues and management.</article-title>
            <source>Ther Adv Musculoskelet Dis</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-20</page-range>
            <pub-id pub-id-type="pmid">22870499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crum-Cianflone</surname>
                <given-names>NF</given-names>
              </name>
            </person-group>
            <article-title>Bacterial, fungal, parasitic, and viral myositis.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>473</fpage>
            <page-range>473-94</page-range>
            <pub-id pub-id-type="pmid">18625683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crum-Cianflone</surname>
                <given-names>NF</given-names>
              </name>
            </person-group>
            <article-title>Infection and musculoskeletal conditions: Infectious myositis.</article-title>
            <source>Best Pract Res Clin Rheumatol</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>1083</fpage>
            <page-range>1083-97</page-range>
            <pub-id pub-id-type="pmid">17127198</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Beshbishi</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Mostafa</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>El-Ganainy</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Parasitic infections and myositis.</article-title>
            <source>Parasitol Res</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>110</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-18</page-range>
            <pub-id pub-id-type="pmid">21881948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szcz&#x00119;sny</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>&#x0015a;wierkocka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Olesi&#x00144;ska</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Differential diagnosis of idiopathic inflammatory myopathies in adults - the first step when approaching a patient with muscle weakness.</article-title>
            <source>Reumatologia</source>
            <year>2018</year>
            <volume>56</volume>
            <issue>5</issue>
            <fpage>307</fpage>
            <page-range>307-315</page-range>
            <pub-id pub-id-type="pmid">30505013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meyer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Schaeffer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gottenberg</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Geny</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sibilia</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Incidence and prevalence of inflammatory myopathies: a systematic review.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-63</page-range>
            <pub-id pub-id-type="pmid">25065005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tazir</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Magy</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Duval</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Le Masson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Duchesne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Couratier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ghorab</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sol&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lacoste</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Goizet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vallat</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>History and current difficulties in classifying inherited myopathies and muscular dystrophies.</article-title>
            <source>J Neurol Sci</source>
            <year>2018</year>
            <month>Jan</month>
            <day>15</day>
            <volume>384</volume>
            <fpage>50</fpage>
            <page-range>50-54</page-range>
            <pub-id pub-id-type="pmid">29249377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ofori</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ramai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ona</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic Dermatomyositis Syndrome Presenting as Dysphagia.</article-title>
            <source>Gastroenterology Res</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-254</page-range>
            <pub-id pub-id-type="pmid">28912913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vignesh</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Balachandran</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kamalanathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hamide</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Myoedema: A clinical pointer to hypothyroid myopathy.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>352</fpage>
            <pub-id pub-id-type="pmid">23776921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cardamone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Darras</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Inherited myopathies and muscular dystrophies.</article-title>
            <source>Semin Neurol</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>250</fpage>
            <page-range>250-9</page-range>
            <pub-id pub-id-type="pmid">18351526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hayat</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kalia</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Guzman</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic Inflammatory Myopathies: Clinical Approach and Management.</article-title>
            <source>Front Neurol</source>
            <year>2016</year>
            <volume>7</volume>
            <fpage>64</fpage>
            <pub-id pub-id-type="pmid">27242652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chiodo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Acquired myopathy/dystrophies.</article-title>
            <source>PM R</source>
            <year>2013</year>
            <month>May</month>
            <volume>5</volume>
            <issue>5 Suppl</issue>
            <fpage>S74</fpage>
            <page-range>S74-80</page-range>
            <pub-id pub-id-type="pmid">23584160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voet</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>van der Kooi</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Riphagen</surname>
                <given-names>II</given-names>
              </name>
              <name>
                <surname>Lindeman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van Engelen</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Geurts</surname>
                <given-names>ACh</given-names>
              </name>
            </person-group>
            <article-title>Strength training and aerobic exercise training for muscle disease.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2010</year>
            <month>Jan</month>
            <day>20</day>
            <issue>1</issue>
            <fpage>CD003907</fpage>
            <pub-id pub-id-type="pmid">20091552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kley</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Tarnopolsky</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vorgerd</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Creatine for treating muscle disorders.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2013</year>
            <month>Jun</month>
            <day>05</day>
            <volume>2013</volume>
            <issue>6</issue>
            <fpage>CD004760</fpage>
            <pub-id pub-id-type="pmid">23740606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katzberg</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Kassardjian</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Toxic and Endocrine Myopathies.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>22</volume>
            <issue>6, Muscle and Neuromuscular Junction Disorders</issue>
            <fpage>1815</fpage>
            <page-range>1815-1828</page-range>
            <pub-id pub-id-type="pmid">27922495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choy</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Hoogendijk</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Lecky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Winer</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2005</year>
            <month>Jul</month>
            <day>20</day>
            <issue>3</issue>
            <fpage>CD003643</fpage>
            <pub-id pub-id-type="pmid">16034905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leclair</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Regardt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wojcik</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>M</given-names>
              </name>
              <collab>Canadian Inflammatory Myopathy Study (CIMS)</collab>
            </person-group>
            <article-title>Health-Related Quality of Life (HRQoL) in Idiopathic Inflammatory Myopathy: A Systematic Review.</article-title>
            <source>PLoS One</source>
            <year>2016</year>
            <volume>11</volume>
            <issue>8</issue>
            <fpage>e0160753</fpage>
            <pub-id pub-id-type="pmid">27504827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedrich</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Van den Berghe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vanhorebeek</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hermans</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.</article-title>
            <source>Physiol Rev</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>95</volume>
            <issue>3</issue>
            <fpage>1025</fpage>
            <page-range>1025-109</page-range>
            <pub-id pub-id-type="pmid">26133937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suresh</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wimalaratna</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Proximal myopathy: diagnostic approach and initial management.</article-title>
            <source>Postgrad Med J</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>89</volume>
            <issue>1054</issue>
            <fpage>470</fpage>
            <page-range>470-7</page-range>
            <pub-id pub-id-type="pmid">23596213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25484.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Osias</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Manno</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Neuromuscular complications of critical illness.</article-title>
            <source>Crit Care Clin</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>785</fpage>
            <page-range>785-94</page-range>
            <pub-id pub-id-type="pmid">25257741</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
